Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Gliomas Clinical Trials

A listing of Gliomas medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (70) clinical trials

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas

OBJECTIVES: - Determine the safety and effectiveness of antineoplastons A10 and AS2-1 in patients with incurable progressive, recurrent, or persistent mixed gliomas following standard therapy. - Assess the response, tolerance to, and side effects of this regimen in these patients. OUTLINE: This is an open label study. Patients receive gradually ...

Phase

Study of Individuals and Families at High Risk for Cancer

OBJECTIVES: - Identify individuals at high risk of cancer, especially due to personal or family medical history. - Evaluate and define clinical spectrum of disease in syndromes predisposing to cancer. - Quantify risks of tumors in family members. - Map, clone, and determine function of tumor susceptibility genes. - Identify ...

Phase N/A

Natural History of Patients With Brain and Spinal Cord Tumors

Background: This protocol is designed to evaluate patients with tumors of the central nervous system (CNS) who appear to be probable candidates for future protocol entry or have disease manifestations that are of unique scientific interest, importance, and/or educational value. Objective: To evaluate patients with tumors of the central nervous ...

Phase N/A

Identification of Genomic Changes in Families Having Multiple Members With Tumors

Genomic changes leading to the formation of brain tumors are slowly being discovered. Despite advances in genomic technology, much analysis is hindered by the lack of control samples that could better delineate genomic alterations leading to disease. The ideal genomic control would be the genetic material of the parents of ...

Phase N/A

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Despite recent advances, glioblastoma multiforme (GBM) remains an incurable malignancy with a short expected survival. c-MET signalling promotes invasive growth and has been described in various cancers. INC280 is a highly potent and selective c-MET inhibitor which also penetrates the blood-brain barrier. In this open-label, multicenter Phase 1b study, investigators ...

Phase

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

Participants will be stratified into four main treatment groups, depending on whether retinoblastoma is present in one or both eyes and disease grouping [early or advanced, Reese-Ellsworth (R-E) group I-V, and International Classification A-E]. Additionally, participants will be invited to participate in exploratory research objectives that address cognitive and functional ...

Phase

Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma

Low-grade gliomas (LGG), the most common of which are pilocytic astrocytomas, diffuse astrocytomas, oligodendrogliomas, and mixed oligo-astrocytomas are a diverse family of central nervous system (CNS) neoplasms that occur in children and adults. Based on data from the American Cancer Society and Central Brain Tumor Registry of the United States ...

Phase

Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors

PRIMARY OBJECTIVES: I. Determine the effect of delayed administration of sodium thiosulfate on the rates of platelet toxicity (i.e. platelet count less than 20,000), in subjects with high-grade glioma undergoing treatment with carboplatin, cyclophosphamide and etoposide/etoposide phosphate. SECONDARY OBJECTIVES: I. Assess tumor response in subjects with high-grade glioma undergoing treatment ...

Phase

Study of VAL-083 in Patients With MGMT Unmethylated Bevacizumab-naive Recurrent Glioblastoma

Recurrent glioblastoma (GBM) is characterized by a dismal prognosis, with a median overall survival of 6-9 months. While a standard of care is established for the initial treatment of GBM - radiation with concurrent and adjuvant temozolomide chemotherapy - management of recurrent disease remains suboptimal. Treatment options include repeat surgery, ...

Phase

Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

Patients that have recurrent glioblastoma that has progressed on bevacizumab continue to receive bevacizumab with the addition of Tumor Treating Fields Therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.

Phase